NIH studying Kowa's statin in HIV

The National Institutes of Health is starting a North American trial of pitavastatin from Kowa Co. Ltd. (Nagoya, Japan) to prevent cardiovascular disease in HIV patients. The double-blind, placebo-controlled 6,500-patient REPRIEVE study will last six years and will enroll HIV patients with no known cardiovascular disease and low risk factors. ...